Applied Therapeutics Inc (NASDAQ:APLT) does about 1.08M shares in volume on a normal day but saw 1803452 shares change hands in the recent trading day. The company now has a market cap of 697.05M USD. Its current market price is $6.10, marking an increase of 1.50% compared to the previous close of $6.01. The 52 week high reached by this stock is $9.39 whilst the lowest price level in 52 weeks is $1.18.
Applied Therapeutics Inc (APLT) has a 20-day trading average at $5.48 and the current price is -35.04% off the 52-week high compared with 416.95% distance from its 52-week low. The 50-day simple moving average of the closing price is $4.95 and its 200-day simple moving average is $4.17. If we look at the stock’s price movements over the week, volatility stands at 13.71%, which decreases to 8.13% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 64.97 to suggest the stock is neutral.
The consensus objective for the share price is $11.40, suggesting that the stock has a potential upside of 46.49% over the period.
3 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
Leerink Partners initiated its price target at $12.
Applied Therapeutics Inc (APLT) stock is up 22.49% over the week and 25.51% over the past month. Its price is 82.09% year-to-date and 242.70% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at -0.16 and -1.14 for whole year. Expected sales for next quarter are $70k, which analysts say will come at $3.72M for the current fiscal year and next year at $54.65M. In addition, estimates put the company’s current quarterly revenue at an average of $2.5M.
To reach the target analysts have set, the stock logically needs to grow 46.49 percent from here.
Outstanding shares total 114.27M with insiders holding 5.95% of the shares and institutional holders owning 89.22% of the company’s common stock. The company has a return on investment of -143.35% and return on equity of -682.16%. The beta has a value of 1.98. Price to book ratio is 10.36 and price to sales ratio is 65.39.
